Journal
JOURNAL OF SURGICAL RESEARCH
Volume 184, Issue 1, Pages 290-298Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.jss.2013.03.049
Keywords
Pancreatic cancer; Orthotopic mouse models; In vivo selection; Kras; Metastasis; Variants; Survival
Categories
Funding
- NCI NIH HHS [CA142669, R33 CA109949, T32 CA121938-5, R01 CA142669, CA132971, R21 CA109949, R01 CA132971, T32 CA121938] Funding Source: Medline
Ask authors/readers for more resources
Introduction: Kras mutations have been thought to play an important role in pancreatic cancer progression. In this study, we evaluated how serially passaging primary pancreatic tumors with and without Kras mutations, in nude mice, can generate more aggressive variants of human pancreatic cancer. Materials & methods: Orthotopic mouse models of human pancreatic cancer were established by injecting 1 x 10(6) cells of the Kras wildtype BxPC-3 cell line, expressing red fluorescent protein or the Kras mutant Panc-1 cell line expressing green fluorescent protein, into the pancreas. Pancreatic tumors were harvested from premorbid mice to establish cell lines. One million passaged cells were then orthotopically injected into another set of mice. Serial passaging continued until decreasing lifespan of the implanted mice stabilized, which occurred by six passages. Mice harboring serially-passaged cell lines were followed with weekly imaging. Results: Serially passaging generated more aggressive variants of both human pancreatic cancer cell lines, one of which was Kras wild-type (BXPC-3) and the other Kras mutant, Panc-1, which displayed faster tumor growth and shortened survival time. Overall survival decreased from 18 wk in mice with the parental cell line (passage 0) tumor to similar to 6 wk in mice by passage 6. Average time to metastasis was shortened from 14 wk to similar to 3 wk or less. At termination, mice with the passaged tumor demonstrated a greater extent of distant metastasis. Conclusions: Serial passaging of tumor creates more aggressive variants of human pancreatic cancer cell lines regardless of Kras mutation. The aggressive variants can be used to study the molecular basis of highly malignant pancreatic cancer and to screen for effective agents against this disease. (C) 2013 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available